Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 98

Humans will achieve immortality by 2030, says futurist

We are currently facing the possibility of achieving immortality for humans by 2030. This prediction comes from renowned futurist Ray Kurzweil, who has a history of making accurate predictions. He anticipates that with the ongoing progress in genetics, robotics, and nanotechnology, we will soon have nanobots coursing through our bloodstream, which could enable us to live forever. It’s truly remarkable to consider that this could be a reality within just seven years.

Nanobots, which are small robots sized between 50–100 nm in width, are currently being used in various clinical medical applications. They are used in research as DNA probes, imaging materials for cells, and targeted delivery vehicles for cells. According to Kurzweil, nanobots represent the future of medicine.

They will be capable of repairing our bodies at a cellular level, making us resistant to diseases, aging, and, ultimately death. Additionally, he theorizes that humans may be able to transfer their consciousness into digital form, leading to immortality.

Scientists Invented a Way to Store Data in Plastic Molecules and It Could Someday Replace Hard Drives

If you thought storing data inside DNA was cool, here’s something even more fascinating. Scientists at the University of Texas at Austin (UT Austin) have invented a way to store digital information inside synthetic polymer molecules. In short, they are transforming tiny bits of plastic into memory banks.

They even used their molecular system to encode a complex 11-character password and then decode it using only electrical signals, without any power, and the expensive and bulky tools typically used for reading molecular data.

Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia

Ischaemic heart disease remains the main cause of death worldwide. 1 Within its multifactorial aetiology low-density lipoprotein (LDL) and other apolipoprotein (apo) B-containing lipoproteins play a central, causal role, promoting the development of the underlying process of atherosclerosis. The use of statins and other drugs—ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, bempedoic acid—to lower LDL is a central strategy in the prevention of atherosclerotic cardiovascular disease (ASCVD) in both primary and secondary settings. 2 However, in many individuals, a substantial ASCVD risk remains after LDL-cholesterol (LDL-C) goal achievement, and elevated plasma triglyceride (TG) is recognised as an important component of this residual risk. 3 Plasma TG, or more specifically TG-rich lipoproteins (TRL), is therefore an additional target for lipid-lowering therapy. Outcome studies of TG lowering using classical drugs such as fibrates and high-dose niacin when added to statins failed to demonstrate further ASCVD risk reduction, although retrospective analyses suggest that subgroups characterised by high TG and low high-density lipoprotein (HDL) may have positive results. 4–7 An alternative approach, treatment with high-dose eicosapentaenoic acid (EPA), has been shown to reduce cardiovascular risk in patients with (and without) hypertriglyceridaemia who are on statins. 8–10

This review explores the concepts behind, and practical implementation of, an evidence-based therapeutic strategy that tailors further intervention according to the plasma lipid profile in patients on standard statin therapy who are often undertreated. 11

Genetic analyses provide robust evidence that elevated TG is a causal risk factor for ASCVD 12 13 and underpin the finding from epidemiological studies that raised TG levels are positively and linearly related to cardiovascular risk (figure 1A). 14 15 The importance of these observations is that they reveal an often unaddressed major risk factor that is of particular relevance in people with obesity or type 2 diabetes in whom TG levels are frequently elevated. 16 Further, outcome trials have shown that elevated TG levels (again especially in type 2 diabetics) are associated with high residual cardiovascular risk in statin-treated patients with established cardiovascular disease, even if they have well-controlled LDL-C. 17–19.

Neurosteroids identified as potential therapy for treatment-resistant depression

Depression, characterized by persistent sadness, hopelessness and a lack of interest in previously enjoyed activities, is one of the most common mental health disorders. Recent estimates by the World Health Organization (WHO) suggest that approximately 5% of the global population suffers from depression.

For decades, researchers have been trying to devise safe and effective treatments for that cause minimal or no side effects. This led to the introduction of a wide range of strategies, ranging from psychotherapy and to a wide range of pharmacological drugs, including (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and atypical antidepressants.

Most people diagnosed with depression eventually find a suitable treatment for them via a trial-and-error process, ultimately leading to their recovery. Some individuals, however, can experience for prolonged periods of time, finding that no treatment ultimately eases their symptoms.

First-of-its-kind device uses single drop of blood to profile newborns’ immune function

Researchers have developed a first-of-its-kind device to profile the immune function of newborns. Using a single drop of blood, the BiophysicaL Immune Profiling for Infants (BLIPI) system provides real-time insights into newborns’ immune responses, enabling the early detection of severe inflammatory conditions and allowing for timely interventions.

This critical innovation addresses the urgent and unmet need for rapid and minimally invasive diagnostic tools to protect vulnerable newborns, especially those born prematurely.

Surgical treatment of multiple breast cancer brain metastases: clinical characteristics and factors impacting postoperative survival

Purpose Breast cancer (BC) is one of the most common primary tumor entities that develop brain metastases (BM) during disease progression. Multiple BM are associated with poorer prognosis, but various surgical, radiotherapeutic and systemic treatment approaches improve survival. We aimed to identify prognostic factors and evaluate the overall survival following BM surgery in patients with multiple BCBM. Methods All metachronous metastasized female patients with resected BCBM at our institution between 2008 and 2019 were included. Data on clinical, radiologic, and histopathologic parameters were recorded and analyzed using univariate and multivariate regression models. Results Among the 93 patients included in the final analysis, 30 individuals presented with multiple BM. Compared to patients with single BM, those with multiple BM were more likely to have infratentorial BM (adjusted odds ratio [aOR] 3.35, 95% confidence interval [CI] 1.03–10.83, p = 0.044), HER2(human epidermal growth factor receptor 2)-positive BC (aOR 3.93, 95% CI 1.23–12.53, p = 0.021) and hepatic metastases (aOR 5.86, 95% CI 1.34–25.61, p = 0.019). There was no significant difference in postoperative survival between individuals with multiple (median: 12.5 months) and single BM (17.0 months, p = 0.186). In the multivariate Cox regression analysis, adjuvant radiotherapy (adjusted hazard ratio [aHR] 5.93, 95% CI 1.06–33.26, p = 0.043) and trastuzumab treatment (aHR 4.95, 95% CI 1.72–14.25, p = 0.003) were associated with longer postoperative survival multiple BCBM patients. Conclusion BC patients with multiple BM show remarkable postoperative survival, particularly if combined with adjuvant radiotherapy. Our data justify the surgery of multiple BCBM in patients with appropriate clinical condition and feasible location of BM.

What If We Could Grow Babies in Artificial Wombs?

The miracle of life. A 40-week process where you developed from a single cell to fully formed human baby. All within in your mother’s womb. Now, imagine you were born in an artifical womb. How would we benefit from artificial wombs? What would be the downsides?

Transcript and sources: https://whatif.show/what-if-we-could–… our Patreon community and help make What If better: http://bit.ly/whatif-patreon Watch more what-if scenarios: Planet Earth: • What If Earth Was in Fact Flat? The Cosmos: • Video Technology: • What If the Sahara Desert Was Covered With… Your Body: • What If You Were Born on a Space Station? Humanity: • What If You Were the Last Person on Earth? Tweet us your what-if question to suggest an episode: http://bit.ly/whatif-twitter What If elsewhere: Instagram: http://bit.ly/whatif-instagram Twitter: http://bit.ly/whatif-twitter Facebook: http://bit.ly/facebook-whatif What If comes in other languages! What If in Spanish: http://bit.ly/YT-Spanish-what-if What If in Mandarin: http://bit.ly/YT-Chinese-what-if Suggest an episode (detailed): http://bit.ly/suggest-whatif T-shirts and merch: http://bit.ly/whatifstore Feedback and inquiries: https://underknown.com/contact/ What If is a mini-documentary web series that takes you on an epic journey through hypothetical worlds and possibilities. Join us on an imaginary adventure — grounded in scientific theory — through time, space and chance, as we ask what if some of the most fundamental aspects of our existence were different.

Join our Patreon community and help make What If better: http://bit.ly/whatif-patreon.

Watch more what-if scenarios:
Planet Earth: • What If Earth Was in Fact Flat?
The Cosmos: • Video.
Technology: • What If the Sahara Desert Was Covered With…
Your Body: • What If You Were Born on a Space Station?
Humanity: • What If You Were the Last Person on Earth?

Tweet us your what-if question to suggest an episode: http://bit.ly/whatif-twitter.

What If elsewhere:

Continue reading “What If We Could Grow Babies in Artificial Wombs?” | >

US approves first blood test for Alzheimer’s

The United States on Friday approved the first blood test for Alzheimer’s, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the devastating neurological disease.

The test, developed by Fujirebio Diagnostics, measures the ratio of two proteins in the blood. The ratio is correlated with amyloid plaques in the brain—a hallmark of Alzheimer’s that, until now, has been detected only through brain scans or spinal fluid analysis.

“Alzheimer’s disease impacts too many people—more than breast cancer and prostate cancer combined,” said Food and Drug Administration Commissioner Marty Makary.